Artiva Biotherapeutics, Inc. SEC filings ARTV
Artiva Biotherapeutics, Inc. has 232 filings in SEC EDGAR's recent list, going back to Jul 10, 2020. Its latest annual report, Form ARS, was filed on Aug 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (results of operations, exit or restructuring costs). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
Oct 27, 2026 | Oct 22, 2026 |
| S-8 | Employee stock plan registration | Sep 11, 2026 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 11, 2026 | Sep 8, 2026 |
| EFFECT | Filing | Aug 14, 2026 | — |
| S-3 | Shelf registration | Aug 6, 2026 | — |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Aug 3, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Other events
|
Jul 22, 2026 | Jul 22, 2026 |
| 8-K |
Current report
Officer or director change
|
May 19, 2026 | May 18, 2026 |
| 8-K |
Current report
Other events
|
May 8, 2026 | May 8, 2026 |
| 424B5 | Prospectus supplement | May 8, 2026 | — |
| FWP | Free writing prospectus | May 8, 2026 | — |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
May 8, 2026 | May 8, 2026 |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
| S-8 | Employee stock plan registration | Mar 10, 2026 | — |
| 10-K | Annual report | Mar 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 10, 2026 | Mar 10, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 24, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 19, 2026 | Feb 18, 2026 |
| 8-K |
Current report
Officer or director change
|
Dec 12, 2025 | Dec 10, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 12, 2025 | Nov 12, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| EFFECT | Filing | Aug 15, 2025 | — |
| CORRESP | Letter to the SEC | Aug 13, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2025 | — |
| S-3 | Shelf registration | Aug 6, 2025 | — |
| S-8 | Employee stock plan registration | Aug 6, 2025 | — |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 25, 2025 | Jun 24, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 29, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Jun 24, 2025 |
| 10-K | Annual report | Mar 24, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2025 | Mar 24, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 29, 2025 | Jan 28, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 22, 2024 | Oct 21, 2024 |
| 10-Q | Quarterly report | Aug 29, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 29, 2024 | Aug 29, 2024 |
| S-8 | Employee stock plan registration | Jul 22, 2024 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jul 22, 2024 | Jul 22, 2024 |
| 424B4 | Prospectus | Jul 22, 2024 | — |
| SEC STAFF LETTER | Filing | Jul 19, 2024 | — |
| EFFECT | Filing | Jul 18, 2024 | — |
| S-1MEF | Filing | Jul 18, 2024 | — |
| CERT | Filing | Jul 18, 2024 | — |
| CORRESP | Letter to the SEC | Jul 16, 2024 | — |
| CORRESP | Letter to the SEC | Jul 16, 2024 | — |
| 8-A12B | Filing | Jul 16, 2024 | — |
| S-1/A | Amended registration statement | Jul 15, 2024 | — |
| CORRESP | Letter to the SEC | Jul 5, 2024 | — |
| CORRESP | Letter to the SEC | Jun 28, 2024 | — |
| S-1 | Registration statement | Jun 28, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2024 | — |
| DRS/A | Filing | Jun 10, 2024 | — |
| DRSLTR | Filing | Jun 7, 2024 | — |
| SEC STAFF LETTER | Filing | May 31, 2024 | — |
| UPLOAD | Letter from the SEC | May 30, 2024 | — |
| DRS | Filing | May 3, 2024 | — |
| RW | Filing | Nov 1, 2022 | — |
| S-1/A | Amended registration statement | Jun 6, 2022 | — |
| S-1/A | Amended registration statement | Mar 7, 2022 | — |
| S-1/A | Amended registration statement | Jan 21, 2022 | — |
| S-1/A | Amended registration statement | Dec 16, 2021 | — |
| S-1 | Registration statement | Apr 8, 2021 | — |
| D | Filing | Apr 5, 2021 | — |
| DRS | Filing | Mar 2, 2021 | — |
| D | Filing | Jul 10, 2020 | — |
Showing 76 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ARTV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1817241
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.